Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,117,161,543.56, representing a 3.59% increase year-over-year[2] - Net profit attributable to shareholders decreased by 6.18% to ¥281,491,538.10 in Q3 2024, while year-to-date net profit increased by 17.97% to ¥973,711,578.04[2] - The total assets at the end of Q3 2024 amounted to ¥9,212,829,093.44, reflecting an 8.01% increase compared to the end of the previous year[2] - The total comprehensive income for the period reached CNY 973,563,490.82, an increase from CNY 825,156,266.48 in the previous period, representing a growth of approximately 17.9%[18] - Basic and diluted earnings per share were both CNY 1.06, up from CNY 0.90 in the same period last year, indicating a 17.8% increase[18] Research and Development - The company reported a significant increase in R&D expenses, which rose by 32.44% to ¥342,158,088.75 compared to the previous year[7] - Research and development expenses increased to CNY 342,158,088.75, compared to CNY 258,348,158.90, marking a rise of 32.5%[16] Cash Flow - The cash flow from operating activities for the year-to-date period increased by 24.72% to ¥1,254,467,611.62[2] - Cash flow from operating activities generated CNY 1,254,467,611.62, compared to CNY 1,005,804,614.23 in the previous year, reflecting a growth of 24.7%[19] - The total cash inflow from operating activities was CNY 3,684,526,280.03, compared to CNY 3,263,788,643.99 in the previous year, marking an increase of 12.9%[19] - Cash inflow from investment activities totaled CNY 2,132,043,970.54, down from CNY 2,729,377,175.51, a decrease of approximately 21.9%[20] - The net cash flow from investment activities was -CNY 2,316,936,761.18, worsening from -CNY 1,951,455,806.19 in the previous year[20] - The company reported a cash outflow from financing activities of -CNY 343,198,374.48, compared to -CNY 130,346,613.38 in the previous year, indicating a significant increase in cash outflow[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,446[8] - Chengdu Kanghong Technology Industry (Group) Co., Ltd. holds 31.75% of shares, totaling 292,014,900 shares[8] - The top ten shareholders hold a combined total of 92.43% of the shares[8] Assets and Liabilities - The total current assets increased to approximately ¥6.20 billion from ¥5.31 billion[13] - The accounts receivable increased to approximately ¥174.09 million from ¥160.41 million[13] - The inventory at the end of the reporting period was approximately ¥404.42 million, slightly up from ¥403.61 million[13] - The company's total liabilities increased to CNY 778,248,708.06 from CNY 717,763,862.41, representing an increase of 8.4%[15] - Deferred income tax assets decreased to CNY 242,661,487.49 from CNY 358,078,120.48, a decline of 32.3%[15] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[17] - The proportion of revenue from traditional Chinese medicine products was 30.68%, with a year-over-year growth of 5.03%[3] - The company experienced a 104.93% increase in revenue from medical devices, reaching ¥1,392.92[3] - The company has received approval for the listing application of fumaric acid volasertib from the National Medical Products Administration[12] - The company also received a drug registration certificate for fumaric acid volasertib tablets on July 17, 2024[12]

证券代码：002773 证券简称：康弘药业 公告编号：2024-053 成都康弘药业集团股份有限公司 第八届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1. 会议以3票同意，0票反对，0票弃权审议通过了《2024年三季 度报告》。 经审核，监事会认为：董事会编制和审核的公司《2024 年三季 1 / 3 度报告》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。同意通过该报告，并同意据此出具监事会 对公司《2024 年三季度报告》无异议的书面审核意见。 《2024 年三季度报告》于 2024 年 10 月 25 日披露在公司指定信 息披露媒体《证券时报》《中国证券报》《上海证券报》《证券日报》 及巨潮资讯网（http://www.cninfo.com.cn）。 2. 会议以3票同意，0票反对，0票弃权审议通过了《关于2022 年股票增值权激励计划第二个行权期行权条件达成的议案》。 经审核，监事会认为：监事会对公司《20 ...

北京市通商（深圳）律师事务所 关于 成都康弘药业集团股份有限公司 2021 年股票期权激励计划 注销部分股票期权的 法律意见书 二〇二四年十月 | 一、本次注销事项的批准与授权 6 | | --- | | 二、本激励计划注销部分股票期权的具体情况 8 | | 三、结论意见 8 | 在本法律意见书内，若出现总数与各分项数值之和尾数不符的情况，均系四 舍五入所致。 3 深圳市南山区南山街道阳光棕榈社区枢纽大街 66 号前海周大福金融大厦（南塔）10 楼 10/F, HyQ, Chow Tai Fook Finance Tower, No. 66 Shu Niu Avenue, Qian Hai, Shenzhen 518052, China 电话 Tel: +86 755 8351 7570 传真 Fax: +86 755 8351 5502 电邮 Email: shenzhen@tongshang.com 网址 Web: www.tongshang.com 北京市通商（深圳）律师事务所 关于成都康弘药业集团股份有限公司 2021 年股票期权激励计划 注销部分股票期权的 释义 在本法律意见书中，除非文中另有说明， ...

成都康弘药业集团股份有限公司 关于2022年股票增值权激励计划第二个行权期 行权条件达成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：002773 证券简称：康弘药业 公告编号：2024-055 特别提示： 1、2022 年股票增值权激励计划第二个行权期行权条件达成，本 次可行权的激励对象总计 1 人，可申请行权的股票增值权数量为 18 万份，占截至 2024 年 9 月 30 日公司总股本 919,778,254.00 股的 0.0196%，尚未符合行权条件的股票增值权数量为 18 万份。 2、本次行权对公司总股本数量无影响，对公司基本每股收益及 净资产收益率影响较小，具体影响以经会计师事务所审计的数据为准， 本次股票增值权行权不会对公司财务状态和经营成果产生重大影响。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开第八届董事会第九次会议、第八届监事会第九次会议， 审议通过了《关于 2022 年股票增值权激励计划第二个行权期行权条 件达成的议案》，根据公司《2022 年股票增值权激励计划(草案）》 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届 董事会第九次会议于2024年10月24日在公司会议室通过现场和通讯 相结合的方式召开。会议通知已于2024年10月18日以书面、传真或 电子邮件等形式向所有董事发出。本次董事会应到董事九名，实到 董事九名（其中：独立董事周德敏先生、邓宏光先生、许楠女士以 通讯方式参加），会议由董事长柯尊洪先生主持，公司监事、董事 会秘书及高级管理人员列席了会议。本次会议的召开符合《中华人 民共和国公司法》和《成都康弘药业集团股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议以书面记名投票方式表决通过了如下决议： 1. 会议以9票赞成、0票反对、0票弃权审议通过了《2024年三季 度报告》。 《2024 年三季度报告》于 2024 年 10 月 25 日披露在公司指定信 1 / 3 证券代码：002773 证券简称：康弘药业 公告编号：2024-052 成都康弘药业集团股份有限公司 第八届董事会第九次会议决议公告 本议案已经薪酬与考核委员会 ...

Investment Rating - The report does not specify a clear investment rating for the company [1]. Core Views - Kanghong Pharmaceutical is a leader in innovative ophthalmic drugs, with a strong pipeline that lays the foundation for long-term growth [1]. - The potential market for the drug Conbercept is vast, with an estimated patient population exceeding 20 million [1][14]. - The company is expanding its product line into Alzheimer's disease and continues to advance its research pipeline [1][22]. Summary by Sections Company Overview - Kanghong Pharmaceutical, established in 1996, focuses on the research, production, and sales of traditional Chinese medicine, chemical drugs, and biological products [8]. - The company has a significant shareholding structure, with the actual controllers holding 56.6% of the shares [9]. Product Performance - Conbercept generated revenue of 1.94 billion yuan in 2023, reflecting a growth of 41.7%, with a compound annual growth rate (CAGR) of 28% from 2015 to 2023 [1][14]. - The drug has been approved for four major indications, including age-related macular degeneration (AMD) and diabetic macular edema (DME), with a patient population exceeding 20 million [14][16]. Research and Development Pipeline - The company is actively pursuing clinical trials for high-concentration Conbercept, which received approval for clinical trials in November 2023 [1][24]. - The pipeline includes innovative gene therapies for ophthalmic conditions, with KH631 and KH658 receiving IND approvals from NMPA and FDA [1][22][26]. - The company is also developing KH110-R01 (Wujia Yizhi Granules) for mild to moderate Alzheimer's disease, with ongoing clinical trials [22][28]. Financial Forecast - The company is projected to achieve net profits of 1.2 billion yuan, 1.38 billion yuan, and 1.54 billion yuan for the years 2024, 2025, and 2026, respectively [1].

证券代码：002773 证券简称：康弘药业 公告编号：2024-051 注册分类：化学药品1类 受理号：CXHL2400797、CXHL2400798、CXHL2400799 成都康弘药业集团股份有限公司 关于公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，成都康弘药业集团股份有限公司（以下简称"公司"） 申报的KH629片临床试验申请获得国家药品监督管理局签发的《药物 临床试验批准通知书》，同意本品开展临床试验。现将相关情况公 告如下： 一、药品基本信息 药品名称：KH629片 剂型：片剂 适应症：本品用于治疗成人非酒精性脂肪性肝炎 成都康弘药业集团股份有限公司董事会 2024 年 10 月 18 日 审批结论：同意本品开展临床试验 二、产品简介 KH629是我公司自主研发的甲状腺激素β受体选择性激动剂，属 于化药1类创新药，剂型为口服固体制剂片剂，2023年11月已获得U.S. Food and Drug Administration(美国食品药品管理局，简称FDA)准 1 / 2 许开展临床试验的通知。已完成的 ...

关于使用自有资金购买理财产品的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第六次会议和二〇二三年度股东大会审议通过了《关于使 用自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲 置自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性 存款），购买原则为安全性高、流动性好、由商业银行发行并提供保本 承诺的短期保本型理财产品（包括结构性存款），购买期限为自股东大 会审议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董 事会授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买 决策权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露 媒体和巨潮资讯网（www.cninfo.com.cn）刊登于2024年4月25日《第八 届董事会第六次会议决议公告》（公告编号：2024-010）及2024年5月17 日《二〇二三年度股东大会决议公告》（公告编号：2024-022）。 近日，公司子公司四川康弘医药贸易有限公司（以 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）董事会于 近日收到公司副总裁何晓蓉女士的书面辞职报告，何晓蓉女士因个人 原因，申请辞去公司副总裁职务。何晓蓉女士辞职后，不再担任公司 及子公司任何职务。 证券代码：002773 证券简称：康弘药业 公告编号：2024-049 成都康弘药业集团股份有限公司 关于公司高级管理人员辞职的公告 特此公告。 成都康弘药业集团股份有限公司董事会 2024 年 9 月 19 日 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》 等法律法规和《公司章程》的相关规定，何晓蓉女士的辞职报告自送 达董事会时生效，何晓蓉女士所负责的工作已安排专人负责妥善交接， 其辞职不会影响公司及子公司相关工作的正常进行。 截至本公告披露日，何晓蓉未持有公司股份；何晓蓉女士为公司 2021 年股票期权激励计划激励对象，总计被授予股票期权 30 万份（截 至本公告披露日，剩余 9 万份已具备行权条件，尚未行权，后续将根 据公司《2021 年股票期权激励计划（草案）》相关规定进行注销。 ...

Group 1: Company Vision and Strategy - The company adheres to the vision of "China Kanghong, World Kanghong, Longqing Kanghong" and focuses on clinical needs in core therapeutic areas such as ophthalmology, neurology, and oncology [1] - The development strategy combines innovation and collaboration, driving high-quality and rapid growth through product innovation and industrial cooperation [1][2] Group 2: Research and Development Focus - The company is intensifying investment in ophthalmology, neurology, and oncology, aiming to launch high-quality new products that meet urgent clinical needs [2][3] - The R&D system includes new drug research institutes and integrates domestic and international resources for professional collaboration [2] Group 3: Financial Performance - In 2023, the company's revenue reached CNY 395,745.96 million, a year-on-year increase of 16.77%, with biopharmaceutical sales growing by 41.73% [4] - For the first half of 2024, revenue was CNY 229,413.17 million, up 19.46%, and net profit was CNY 69,222.00 million, up 31.77% [4] Group 4: Market Position and Competitive Landscape - The company has multiple first-class new drugs with international patents and is actively exploring international markets [2][3] - The company maintains a competitive edge in the ophthalmology market, particularly with its product, Conbercept, which has shown consistent growth over the past decade [6] Group 5: Supply Chain and Production Capacity - The company has established six traditional Chinese medicine planting bases across four provinces, covering over 4,000 acres, ensuring traceability and modern management practices [3] - The company has laid out production capacity for traditional Chinese medicine and chemical raw materials to mitigate risks from raw material price fluctuations [3] Group 6: Future Growth and Innovation - The company expects revenue and net profit to grow by 10%-20% in 2024 compared to 2023 [5] - The company is focusing on innovative research in gene therapy, synthetic biology, and antibody development to address high-incidence diseases and chronic conditions [2][5]